New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:29 EDTSRPTSarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports
According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review. Reference Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:01 EDTSRPTSarepta enters into partnership with Flagship Biosciences
Sarepta Therapeutics and Flagship Biosciences announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy drug pipeline, including its lead candidate, eteplirsen. This newly established collaboration with Flagship demonstrates Sarepta’s commitment to enhancing the objective measurement of dystrophin in tissue samples for its growing pipeline of RNA-based therapeutics to treat DMD.
August 7, 2014
07:38 EDTSRPTSarepta reports Q2 EPS (61c), consensus (76c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use